Cargando…

Dynamics of pseudo‐atrophy in RRMS reveals predominant gray matter compartmentalization

OBJECTIVE: To assess the dynamics of “pseudo‐atrophy,” the accelerated brain volume loss observed after initiation of anti‐inflammatory therapies, in patients with multiple sclerosis (MS). METHODS: Monthly magnetic resonance imaging (MRI) data of patients from the IMPROVE clinical study (NCT00441103...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Stefano, Nicola, Giorgio, Antonio, Gentile, Giordano, Stromillo, Maria Laura, Cortese, Rosa, Gasperini, Claudio, Visconti, Andrea, Sormani, Maria Pia, Battaglini, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951094/ https://www.ncbi.nlm.nih.gov/pubmed/33534940 http://dx.doi.org/10.1002/acn3.51302

Ejemplares similares

Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets
por: Cortese, Rosa, et al.
Publicado: (2022)

Learning ability correlates with brain atrophy and disability progression in RRMS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Mapping the Progressive Treatment-Related Reduction of Active MRI Lesions in Multiple Sclerosis
por: Giorgio, Antonio, et al.
Publicado: (2020)

Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2016)

Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2011)

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
por: De Stefano, Nicola, et al.
Publicado: (2017)

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
por: Ghezzi, Angelo, et al.
Publicado: (2019)

Deep gray matter volume loss drives disability worsening in multiple sclerosis
por: Eshaghi, Arman, et al.
Publicado: (2018)

Atrophy in subcortical gray matter in adult patients with moyamoya disease
por: Zuo, Zhiwei, et al.
Publicado: (2023)

Gray Matter Correlates of Cognitive Performance Differ between Relapsing-Remitting and Primary-Progressive Multiple Sclerosis
por: Jonkman, Laura E., et al.
Publicado: (2015)

Oral available agents in the treatment of RRMS
por: Aupérin, Thierry
Publicado: (2013)

Progression of regional grey matter atrophy in multiple sclerosis
por: Eshaghi, Arman, et al.
Publicado: (2018)

EDSS and infratentorial white matter lesion volume are considered predictors of fatigue severity in RRMS
por: Ezzeldin, Mohammed Y., et al.
Publicado: (2023)

Regional Gray Matter Atrophy Coexistent with Occipital Periventricular White Matter Hyper Intensities
por: Duan, Dazhi, et al.
Publicado: (2016)

Gray matter atrophy rate as a marker of disease progression in AD
por: Anderson, Valerie M., et al.
Publicado: (2012)

The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016)

Patterns of Cerebellar Gray Matter Atrophy Across Alzheimer’s Disease Progression
por: Toniolo, Sofia, et al.
Publicado: (2018)

Gray Matter Atrophy to Explain Subclinical Oculomotor Deficit in Multiple Sclerosis
por: Kincses, Bálint, et al.
Publicado: (2019)

Spinal cord gray matter atrophy is associated with functional decline in post‐polio syndrome
por: Wendebourg, Maria Janina, et al.
Publicado: (2022)

Th17 cells increase in RRMS as well as in SPMS, whereas various other phenotypes of Th17 increase in RRMS only
por: Kalra, S, et al.
Publicado: (2020)

Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study
por: Cash, David M., et al.
Publicado: (2018)

Regional gray matter atrophy and neuropsychologcal problems in relapsing-remitting multiple sclerosis
por: Lin, Aiyu, et al.
Publicado: (2013)

Voxel-Based Meta-Analysis of Gray Matter Abnormalities in Multiple System Atrophy
por: Lin, Junyu, et al.
Publicado: (2020)

Brain Gray Matter Atrophy and Functional Connectivity Remodeling in Patients With Chronic LHON
por: Tian, Qin, et al.
Publicado: (2022)

Gray and white matter alterations in different predominant side and type of motor symptom in Parkinson's disease
por: Chen, Jingwen, et al.
Publicado: (2022)

Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis: A Systematic Review
por: Lie, Ingrid Anne, et al.
Publicado: (2022)

Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers
por: Bussas, Matthias, et al.
Publicado: (2021)

Distinct binding properties of TIAR RRMs and linker region
por: Kim, Henry S., et al.
Publicado: (2013)

Global gray matter changes in posterior cortical atrophy: A serial imaging study
por: Lehmann, Manja, et al.
Publicado: (2012)

Patterns of gray matter atrophy in atypical parkinsonism syndromes: a VBM meta-analysis
por: Yu, Fang, et al.
Publicado: (2015)

Midlife Work-Related Stress is Associated with Late-Life Gray Matter Volume Atrophy
por: Sindi, Shireen, et al.
Publicado: (2017)

Identifying miRNAs in multiple sclerosis gray matter lesions that correlate with atrophy measures
por: Tripathi, Ajai, et al.
Publicado: (2021)

Association between gray matter atrophy, cerebral hypoperfusion, and cognitive impairment in Alzheimer’s disease
por: Dong, Haoyang, et al.
Publicado: (2023)

The causal link between cardiometabolic risk factors and gray matter atrophy: An exploratory study
por: Vigneshwaran, Vibujithan, et al.
Publicado: (2023)

Molecular compartmentalization of lateral geniculate nucleus in the gray squirrel (Sciurus carolinensis)
por: Felch, Daniel L., et al.
Publicado: (2012)

Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice
por: Mehta, Devangi, et al.
Publicado: (2019)

Cerebellar Information Processing in Relapsing-Remitting Multiple Sclerosis (RRMS)
por: Lesage, E., et al.
Publicado: (2010)

Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy
por: Vališ, Martin, et al.
Publicado: (2020)

Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis()
por: Nakamura, Kunio, et al.
Publicado: (2013)

Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment
por: Koskimäki, Fredrika, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c0n7mcbs8dtidce5cmnt72kri2